DOES THE REAL-WORLD USE OF PHARMACOLOGICAL THERAPY FOLLOW GUIDELINES IN CORONARY ARTERY DISEASE PATIENTS IN FINLAND?
Author(s)
Heiskanen J1, Hartikainen J1, Martikainen JA2, Miettinen H1, Hippeläinen M1, Roine RP2, Tolppanen A2
1Kuopio University Hospital, Kuopio, Finland, 2University of Eastern Finland, Kuopio, Finland
OBJECTIVES: Optimal medical therapy (OMT) is essential for symptom control and primary and secondary prevention of coronary artery disease (CAD). Guideline-recommended OMT in CAD consist of at least acetylsalicylic acid, lipid lowering drugs and beta blockers. In addition, angiotensin-converting enzyme -inhibitors or angiotensin receptor blocking agents may be indicated for some patients, and adenosine diphosphate (ADP) receptor inhibitors for patients having undergone a percutaneous coronary intervention (PCI). We studied how well the purchases of the most important OMT drugs followed guidelines in CAD patients before and after elective revascularization by PCI or coronary artery bypass grafting (CABG). METHODS: Clinical data from Kuopio University Hospital revascularization registers (years 2007-2014) were linked to national registers on mortality, hospital discharges, and prescription drugs purchased by the patients. Drugs were classified according to the Anatomical Therapeutic Chemical (ATC)-classification system and cardiovascular drugs were identified as any ATC-code C drug. RESULTS: CONCLUSIONS: Based on information on drug purchases, real-world use of recommended pharmacological therapy before and after revascularization complied both in PCI and CABG patients surprisingly well with current guidelines.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PCV141
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Cardiovascular Disorders